Cost Comparison of Cancer Treatments
Author Information
Author(s): Almond J, Ralston S
Primary Institution: Merck Pharmaceuticals
Hypothesis
The cost-effectiveness of oral fluoropyrimidine treatment for metastatic colorectal cancer is being misrepresented.
Conclusion
The authors argue that the costs associated with Uftoral® treatment are lower than previously reported and that inaccuracies in cost estimations could mislead clinicians.
Supporting Evidence
- The price of Uftoral® was reduced by 59%, making it cheaper than other therapies.
- The authors dispute the accuracy of cost estimations related to adverse events.
- They argue that the adverse event costs for Uftoral® should be lower than those for capecitabine.
Takeaway
This article says that a cancer treatment called Uftoral® is cheaper than what was previously thought, and some of the costs reported might not be correct.
Potential Biases
There may be an overestimation of adverse event costs for Uftoral® compared to capecitabine.
Limitations
The authors highlight discrepancies in cost estimations and the potential for bias in the reported data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website